Use and cardiovascular safety of transdermal and other granisetron preparations in cancer management.

Abstract

5-HT3 antagonists have been available as oral and intravenous preparations for decades. The availability more recently of transdermal granisetron and the anticipated availability of a subcutaneous granisetron preparation have provided helpful alternatives to patients, and these preparations have been shown to have less potential to prolong QT than other drugs in the class.

• Authors: Jay W Mason, Thomas E Moon
• Journal: Cancer management and research (Cancer Manag Res) Vol. 5 Pg. 179-85 ( 2013) ISSN: 1179-1322 [Print] New Zealand
• PMID: 23930078 (Publication Type: Journal Article)